Investing.com – Allergan (NYSE:AGN_pa) beat EPS forecasts but revenues missed target.
The maker of Botox’s diluted Q2 EPS came in at $3.35 against a forecast of $3.34.
Revenues totalled $3.71 bn against an estimate of $4.11 bn.
Allergan booked Q2 2015 EPS of $3.67 on revenues of $3.67 bn.